Christopher Twelves, MD: Comparing Eribulin and Capecitabine

Dr. Christopher Twelves sits down with Selma Schimmel and The Group Room at the 35th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).  They discuss the results of the Phase III clinical trial comparing capecitabine (Xeloda) and eribulin (Halaven).  The trial showed trends toward the superiority of eribulin in this setting but the results were still considered to be statistically negative overall, but not for triple-negative breast cancer patients.

Christopher Twelves, MD, Professor and Honorary Consultant in Medical Oncology, University of Leeds in the United Kingdom.

Advocacy and educational support provided in part by:

Eisai Lilly Logos SABCS 2012

Comments